INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15001, 33379, 'Pantoprazole', 'Clostridium Infections', 'Published observational studies suggest that proton pump inhibitor (PPI) use may be associated with an increased risk of Clostridium difficile-associated diarrhea (CDAD), especially in hospitalized patients.  This diagnosis should be considered for diarrhea that does not improve.  It is recommended that patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Close monitoring is recommended in patients with diarrhea and in those taking antibacterial agents as CDAD has been reported with the use of nearly all these agents.  Treatment with antibacterial agents alters the normal flora of the colon, leading to overgrowth of C.  difficile.  C.  difficile produces toxins A and B, which contribute to the development of CDAD.  Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C.  difficile, and surgical evaluation should be instituted as clinically indicated.', '3', '"Product Information. PriLOSEC (omeprazole)." Merck & Co., Inc  (2022):|"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Protonix IV (pantoprazole)." Wyeth-Ayerst Laboratories|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):|"Product Information. NexIUM I.V. (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2014):|"Product Information. Esomeprazole Strontium (esomeprazole)." Amneal Pharmaceuticals  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15002, 818, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15003, 820, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15004, 1023, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15005, 3012, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15006, 3014, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15007, 3385, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15008, 4351, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15009, 4354, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15010, 5128, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15011, 5716, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15012, 6282, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15013, 9581, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15014, 9607, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15015, 9608, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15016, 9610, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15017, 9611, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15018, 9612, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15019, 11420, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15020, 12942, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15021, 12943, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15022, 12944, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15023, 12945, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15024, 14263, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15025, 16765, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15026, 17215, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15027, 19510, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15028, 19511, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15029, 22159, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15030, 24508, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15031, 24538, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15032, 24539, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15033, 24540, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15034, 24720, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15035, 24721, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15036, 24768, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15037, 24769, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15038, 25424, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15039, 25425, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15040, 25426, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15041, 25429, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15042, 25430, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15043, 27577, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15044, 31822, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15045, 33375, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15046, 33379, 'Pantoprazole', 'Liver Diseases', 'Pantoprazole is primarily metabolized by the liver.  In patients with mild to moderate hepatic impairment, little drug accumulation has been observed following once-daily, multiple-dose administration.  No dosage adjustments are necessary in these patients.  However, data are limited concerning the pharmacokinetic disposition of pantoprazole in patients with severe hepatic impairment.  Alternate-day dosing may be appropriate in some cases.', '2', '"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15047, 818, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15048, 820, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15049, 1023, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15050, 3012, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15051, 3014, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15052, 3385, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15053, 4351, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15054, 4354, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15055, 5128, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15056, 5716, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15057, 6282, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15058, 9581, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15059, 9607, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15060, 9608, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15061, 9610, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15062, 9611, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15063, 9612, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15064, 11420, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15065, 12942, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15066, 12943, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15067, 12944, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15068, 12945, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15069, 14263, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15070, 16765, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15071, 17215, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15072, 19510, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15073, 19511, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15074, 22159, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15075, 24508, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15076, 24538, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15077, 24539, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15078, 24540, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15079, 24720, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15080, 24721, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15081, 24768, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15082, 24769, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15083, 25424, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15084, 25425, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15085, 25426, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15086, 25429, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15087, 25430, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15088, 27577, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15089, 31822, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15090, 33375, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15091, 33379, 'Pantoprazole', 'Fractures, Bone', 'Various published observational studies have reported that PPI therapy may be associated with an increased risk for osteoporosis related fractures of the hip, wrist or spine.  The risk was increased in patients who received high doses (multiple daily doses), and long term treatment (a year or longer).  Patients should use the lowest dose and shortest duration of PPI therapy appropriate to the condition being treated.  Caution should be used in patients at risk for osteoporosis related fractures and should be managed according to established treatment guidelines.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15092, 818, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15093, 820, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15094, 1023, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15095, 3012, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15096, 3014, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15097, 3385, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15098, 4351, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15099, 4354, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15100, 5128, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15101, 5716, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15102, 6282, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15103, 9581, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15104, 9607, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15105, 9608, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15106, 9610, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15107, 9611, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15108, 9612, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15109, 11420, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15110, 12942, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15111, 12943, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15112, 12944, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15113, 12945, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15114, 14263, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15115, 16765, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15116, 17215, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15117, 19510, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15118, 19511, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15119, 22159, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15120, 24508, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15121, 24538, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15122, 24539, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15123, 24540, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15124, 24720, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15125, 24721, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15126, 24768, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15127, 24769, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15128, 25424, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15129, 25425, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15130, 25426, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15131, 25429, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15132, 25430, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15133, 27577, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15134, 31822, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15135, 33375, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15136, 33379, 'Pantoprazole', 'Hypomagnesemia 1, Intestinal', 'Symptomatic and asymptomatic hypomagnesemia has been reported rarely in patients treated with PPIs for at least 3 months, in most cases after a year of therapy.  Serious adverse events can include tetany, seizures, and arrhythmias.  Caution should be used in patients prone to magnesium imbalances such as patients taking other medications that can cause hypomagnesemia (e.g., diuretics).  Regular monitoring is recommended.', '2', '"Product Information. Prevacid (lansoprazole)." TAP Pharmaceuticals Inc  (2001):|"Product Information. Aciphex (rabeprazole)." Janssen Pharmaceuticals  (2001):|"Product Information. Protonix (pantoprazole)." Wyeth-Ayerst Laboratories  (2001):|"Product Information. Nexium (esomeprazole)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Omeprazole (omeprazole)." Mylan Pharmaceuticals Inc  (2003):|"Product Information. Kapidex (dexlansoprazole)." Takeda Pharmaceuticals America  (2009):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15137, 0, 'Parathyroid hormone', 'Hyperparathyroidism', 'Patients known to have an underlying hypercalcemic disorder, such as primary hyperparathyroidism, should not be treated with parathyroid hormone and its analogs because of the risk of exacerbating hypercalcemia.', '3', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):|"Product Information. Natpara (parathyroid hormone)." NPS Pharmaceuticals  (2015):|"Product Information. Tymlos (abaloparatide)." Radius Health  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15138, 0, 'Parathyroid hormone', 'Neoplasms', 'Parathyroid hormone and its analogs should not be used in patients who are at increased baseline risk for osteosarcoma.  These agents should only be used if the potential benefits are considered to outweigh the potential risks.  Monitor these patients according to clinical guidelines.  Patients with bone metastases or a history of skeletal malignancies should not be treated with these agents.', '3', '"Product Information. Forteo (teriparatide)." Lilly, Eli and Company  (2002):|"Product Information. Natpara (parathyroid hormone)." NPS Pharmaceuticals  (2015):|"Product Information. Tymlos (abaloparatide)." Radius Health  (2017):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15139, 0, 'Parathyroid hormone', 'Kidney Diseases', 'Parathyroid hormone is eliminated by the kidney and maximum drug levels increased with renal impairment.  No dose adjustment is recommended in patients with mild to moderate renal impairment.  No studies have been conducted in patients with severe renal impairment or in renal impairment patients on dialysis.  Care and close monitoring should be exercised when using this agent in patients with severe renal impairment or on dialysis.', '2', '"Product Information. Natpara (parathyroid hormone)." NPS Pharmaceuticals  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15140, 9657, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15141, 9669, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15142, 10366, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15143, 10367, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15144, 17265, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15145, 24597, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15146, 24598, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15147, 24601, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15148, 24602, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15149, 24603, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15150, 33383, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15151, 33384, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15152, 33385, 'Paroxetine', 'Depressive Disorder', 'Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior.  Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes.  Families and caregivers should be advised of the need for close observation and communication with the treating physician.  Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset.  It may be prudent to refrain from dispensing large quantities of medication to these patients.', '3', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15153, 9657, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15154, 9669, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15155, 10366, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15156, 10367, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15157, 17265, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15158, 24597, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15159, 24598, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15160, 24601, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15161, 24602, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15162, 24603, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15163, 33383, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15164, 33384, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15165, 33385, 'Paroxetine', 'Fractures, Bone', 'Some epidemiological studies have reported association between antidepressant treatment and bone fractures.  The extent of this risk is unknown.  Treatment with paroxetine should be administered with caution in patients with decreased bone mineral density that present unexplained bone pain, tenderness, swelling or bruising.', '2', '"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15166, 9657, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15167, 9669, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15168, 10366, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15169, 10367, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15170, 17265, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15171, 24597, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15172, 24598, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15173, 24601, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15174, 24602, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15175, 24603, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15176, 33383, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15177, 33384, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15178, 33385, 'Paroxetine', 'Kidney Diseases', 'Paroxetine may accumulate in renal dysfunction.  The mean plasma concentration of paroxetine in patients with creatinine clearance below 30 mL/min has been shown to be approximately four times greater than that in normal patients.  Therapy with paroxetine should be administered cautiously in patients with renal impairment.  A reduction in the daily dosage is recommended if renal function is severely impaired.', '2', 'Doyle GD, Laher M, Kelly JG, Byrne MM, Clarkson A, Zussman BD "The pharmacokinetics of paroxetine in renal impairment." Acta Psychiatr Scand Suppl 350 (1989):  89-90|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15179, 9657, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15180, 9669, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15181, 10366, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15182, 10367, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15183, 17265, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15184, 24597, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15185, 24598, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15186, 24601, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15187, 24602, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15188, 24603, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15189, 33383, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15190, 33384, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15191, 33385, 'Paroxetine', 'Hyponatremia', 'Treatment with SSRI antidepressants can cause hyponatremia.  Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15192, 9657, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15193, 9669, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15194, 10366, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15195, 10367, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15196, 17265, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15197, 24597, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15198, 24598, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15199, 24601, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15200, 24602, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15201, 24603, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15202, 33383, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15203, 33384, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15204, 33385, 'Paroxetine', 'Glaucoma', 'Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation.  This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients.  These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.', '2', '"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15205, 9657, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15206, 9669, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15207, 10366, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15208, 10367, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15209, 17265, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15210, 24597, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15211, 24598, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15212, 24601, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15213, 24602, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15214, 24603, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15215, 33383, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15216, 33384, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15217, 33385, 'Paroxetine', 'Liver Diseases', 'Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver.  The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function.  Dosage adjustments may be necessary in accordance with the individual product package labeling.', '2', 'Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988):  353-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982):  351-7|Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989):  91-2|Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989):  60-75|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic  properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986):  313-34|Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993):  895-924|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994):  1359-69|van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993):  203-20|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15218, 9657, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15219, 9669, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15220, 10366, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15221, 10367, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15222, 17265, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15223, 24597, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15224, 24598, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15225, 24601, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15226, 24602, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15227, 24603, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15228, 33383, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15229, 33384, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15230, 33385, 'Paroxetine', 'Mania', 'Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania.  The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs.  Patients with bipolar disorder are generally more likely to experience mania from antidepressants.  Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder.  Prior to initiating treatment, it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.', '2', 'Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992):  1282-3|Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991):  1751|Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991):  1404|Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990):  1569|Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992):  107|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987):  1513-4|Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993):  689-90|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993):  698-9|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994):  549-50|Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991):  1263-4|Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993):  1455-7|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991):  391-2|Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994):  78-9|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996):  425-7|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15231, 9657, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15232, 9669, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15233, 10366, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15234, 10367, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15235, 17265, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15236, 24597, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15237, 24598, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15238, 24601, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15239, 24602, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15240, 24603, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15241, 33383, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15242, 33384, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15243, 33385, 'Paroxetine', 'Blood Platelet Disorders', 'The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function.  Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported.  Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.', '2', 'Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992):  412|Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991):  949|Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990):  727-8|Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992):  1517-9|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994):  781-2|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995):  132|Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996):  12-6|Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996):  786-8|Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996):  1232-4|Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996):  604-5|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000):  435-42', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15244, 9657, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15245, 9669, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15246, 10366, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15247, 10367, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15248, 17265, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15249, 24597, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15250, 24598, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15251, 24601, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15252, 24602, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15253, 24603, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15254, 33383, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15255, 33384, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15256, 33385, 'Paroxetine', 'Epilepsy', 'Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy.  Therapy with SSRIs should be administered cautiously in patients with seizure disorders.', '2', 'Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992):  236-9|Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988):  46-51|Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991):  952-61|Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992):  604-24|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992):  61-6|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993):  603-30|Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994):  145-6|Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994):  383-4|Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994):  127-38|Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993):  321|Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991):  433-5|Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994):  387-95|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995):  1238-9|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000):  1276-8|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15257, 9657, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15258, 9669, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15259, 10366, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15260, 10367, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15261, 17265, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15262, 24597, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15263, 24598, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15264, 24601, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15265, 24602, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15266, 24603, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15267, 33383, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15268, 33384, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15269, 33385, 'Paroxetine', 'Inappropriate ADH Syndrome', 'The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH).  These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention.  SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy.  Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH.  Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.', '2', 'Abbott R "Hyponatremia due to antidepressant medications." Ann Emerg Med 12 (1983):  708-10|Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991):  542-3|Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990):  1569-70|Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990):  948-9|Kazal LA, Jr  Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993):  341-3|Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993):  1564|Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993):  723-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993):  143|Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992):  1332|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994):  779-80|Pillans PI, Coulter DM "Fluoxetine and hyponatraemia - a potential hazard in the elderly." N Z Med J 107 (1994):  85-6|Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993):  62-3|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994):  543-4|Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995):  809|Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995):  809-10|Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995):  390|Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996):  524|Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996):  680-3|"Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996):  562|Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996):  885|Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996):  1413|Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997):  108-10|Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997):  580|Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997):  93-5|Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997):  306-7|Liu BA, Mittmann N, Knowles SR, Shear NH "Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotoni reuptake inhibitors: a review of spontaneous reports [publishe erratum appears in Can Med Assoc J 1996 Oct 15;155(8):1043." CMAJ 155 (1996):  519-27|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):|Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998):  25-30|"Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals  (2002):|Palmer BF, Gates JR, Lader M "Causes and management of hyponatremia." Ann Pharmacother 37 (2003):  1694-702|Twardowschy CA, Bertolucci CB, Gracia Cde M, Brandao MA "Severe hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) associated with fluoxetine: case report." Arq Neuropsiquiatr 64 (2006):  142-5', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15270, 9657, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15271, 9669, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15272, 10366, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15273, 10367, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15274, 17265, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15275, 24597, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15276, 24598, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15277, 24601, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15278, 24602, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15279, 24603, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15280, 33383, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15281, 33384, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15282, 33385, 'Paroxetine', 'Weight Loss', 'The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss.  Anorexia may occur in approximately 5% to 10% of patients.  Weight change should be monitored during therapy if an SSRI is used in these patients.', '1', 'Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992):  1113-4|"Product Information. Zoloft (sertraline)." Roerig Division  (2001):|"Product Information. Prozac (fluoxetine)." Dista Products Company  (2001):|"Product Information. Paxil (paroxetine)." GlaxoSmithKline  (2001):|Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994):  118-9|Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994):  1176-81|Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988):  948-9|Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992):  48-53;disc. 53-4|"Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc  (2001):|Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994):  1350-2|"Product Information. Celexa (citalopram)." Forest Pharmaceuticals  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15283, 29870, 'Paricalcitol', 'Arrhythmias, Cardiac', 'Paricalcitol, a vitamin D analog, reduces hyperparathyroidism associated with chronic renal failure without significant increase in serum calcium levels.  Serum calcium and phosphate concentrations can increase during therapy with paricalcitol and may exacerbate arrhythmias, particularly in patients receiving cardiac glycosides.  Therapy with vitamin D analogs should be administered cautiously in patients with or predisposed to cardiac arrhythmias.  Clinical monitoring of serum electrolyte concentrations and cardiac function is recommended. .', '3', '"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15284, 29870, 'Paricalcitol', 'Water-Electrolyte Imbalance', 'Vitamin D analogs administered in the presence of hyperphosphatemia can result in precipitation of calcium-phosphate deposits within the vascular or  renal systems or other soft tissue calcifications.  A solubility product (Serum Calcium X Phosphate) should not exceed 70.  Serum electrolyte concentrations should be corrected prior to vitamin D analog therapy and monitored during therapy.', '3', '"Product Information. Calciferol (ergocalciferol)." Schwarz Pharma  (2001):|"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Calderol (calcifediol)." Organon  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15285, 29870, 'Paricalcitol', 'Hypercalcemia', 'Vitamin D analogs such as calciferol and ergocalciferol should not be given to patients with hypercalcemia, malabsorption syndrome, or evidence of vitamin D toxicity.', '3', '"Product Information. Rocaltrol (calcitriol)." Roche Laboratories  (2001):|"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):|"Product Information. Delta D3 (cholecalciferol)." Freeda Vitamins Inc  (2002):|"Product Information. Drisdol (ergocalciferol)." sanofi-aventis  (2016):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15286, 29870, 'Paricalcitol', 'Liver Diseases', 'Paricalcitol is metabolized by the liver. Parent compound and metabolites are primarily eliminated by in the bile and feces.  Paricalcitol metabolites have not been characterized or identified. Metabolic and therapeutic activity of paricalcitol may be altered in patients with hepatic impairment.  Therapy with paricalcitol should be administered cautiously in patients with hepatobiliary dysfunction.  Clinical monitoring of hepatobiliary function, parathyroid hormone and calcium levels is recommended.', '2', '"Product Information. Zemplar (paricalcitol)." Abbott Pharmaceutical  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15287, 0, 'Paromomycin', 'Intestinal Obstruction', 'The use of oral aminoglycosides is contraindicated in patients with intestinal obstruction.  Orally administered aminoglycosides are poorly absorbed from the gastrointestinal tract and primarily eliminated unchanged in the feces.  Drug retention and enhanced systemic absorption may occur in the presence of intestinal obstruction, increasing the risk of oto- and nephrotoxicity associated with these drugs.', '3', 'Ristuccia AM, Cunha BA "The aminoglycosides." Med Clin North Am 66 (1982):  303-12|"Product Information. Humatin (paromomycin)." Parke-Davis  (2001):|"Product Information. Mycifradin (neomycin)." Emerson Laboratories  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15288, 0, 'Paromomycin', 'Colitis', 'Clostridioides difficile-associated diarrhea (CDAD), formerly pseudomembranous colitis, has been reported with almost all antibacterial drugs and may range from mild diarrhea to fatal colitis.  The most common culprits include clindamycin and lincomycin.  Antibacterial therapy alters the normal flora of the colon, leading to overgrowth of C difficile, whose toxins A and B contribute to CDAD development.  Morbidity and mortality are increased with hypertoxin-producing strains of C difficile; these infections can be resistant to antimicrobial therapy and may require colectomy.  CDAD must be considered in all patients who present with diarrhea after antibacterial use.  Since CDAD has been reported to occur more than 2 months after antibacterial use, careful medical history is necessary.  Therapy with broad-spectrum antibacterials and other agents with significant antibacterial activity should be administered cautiously in patients with history of gastrointestinal disease, particularly colitis; pseudomembranous colitis (generally characterized by severe, persistent diarrhea and severe abdominal cramps, and sometimes associated with the passage of blood and mucus), if it occurs, may be more severe in these patients and may be associated with flares in underlying disease activity.  Antibacterial drugs not directed against C difficile may need to be stopped if CDAD is suspected or confirmed.  Appropriate fluid and electrolyte management, protein supplementation, antibacterial treatment of C difficile, and surgical evaluation should be started as clinically indicated.', '3', '"Product Information. Omnipen (ampicillin)." Wyeth-Ayerst Laboratories  (2002):|"Product Information. Ceftin (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Zinacef (cefuroxime)." Glaxo Wellcome  (2002):|"Product Information. Cleocin (clindamycin)." Pharmacia and Upjohn  (2002):|"Product Information. Macrobid (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Macrodantin (nitrofurantoin)." Procter and Gamble Pharmaceuticals  (2002):|"Product Information. Amoxil (amoxicillin)." SmithKline Beecham  (2001):|"Product Information. Merrem (meropenem)." Astra-Zeneca Pharmaceuticals  (2001):|"Product Information. Coly-Mycin M Parenteral (colistimethate)." Parke-Davis  (2001):|"Product Information. Lincocin (lincomycin)." Pharmacia and Upjohn  (2001):|"Product Information. Cubicin (daptomycin)." Cubist Pharmaceuticals Inc  (2003):|"Product Information. Xifaxan (rifaximin)." Salix Pharmaceuticals  (2004):|"Product Information. Doribax (doripenem)." Ortho McNeil Pharmaceutical  (2007):|"Product Information. Penicillin G Procaine (procaine penicillin)." Monarch Pharmaceuticals Inc  (2009):|"Product Information. Vibativ (telavancin)." Theravance Inc  (2009):|"Product Information. Teflaro (ceftaroline)." Forest Pharmaceuticals  (2010):|"Product Information. Penicillin G Sodium (penicillin G sodium)." Sandoz Inc  (2022):|"Product Information. Dalvance (dalbavancin)." Durata Therapeutics, Inc.  (2014):|"Product Information. Orbactiv (oritavancin)." The Medicines Company  (2014):|"Product Information. Bicillin C-R (benzathine penicillin-procaine penicillin)." A-S Medication Solutions  (2017):|"Product Information. Baxdela (delafloxacin)." Melinta Therapeutics, Inc.  (2017):|"Product Information. Polymyxin B Sulfate (polymyxin B sulfate)." AuroMedics Pharma LLC  (2022):|"Product Information. Zemdri (plazomicin)." Achaogen  (2018):|"Product Information. Seysara (sarecycline)." Allergan Inc  (2018):|"Product Information. Nuzyra (omadacycline)." Paratek Pharmaceuticals, Inc.  (2018):|"Product Information. Aemcolo (rifamycin)." Aries Pharmaceuticals, Inc.  (2018):|"Product Information. Fetroja (cefiderocol)." Shionogi USA Inc  (2019):|"Product Information. Biaxin (clarithromycin)." AbbVie US LLC  (2019):|"Product Information. Zithromax (azithromycin)." Pfizer U.S. Pharmaceuticals Group  (2021):|"Product Information. E.E.S.-400 Filmtab (erythromycin)." Arbor Pharmaceuticals  (2018):|"Product Information. Priftin (rifapentine)." sanofi-aventis  (2020):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15289, 0, 'Paromomycin', 'Gastroenteritis', 'Like other aminoglycosides, paromomycin is potentially oto- and nephrotoxic.  While it is poorly absorbed from the gastrointestinal tract, significant systemic absorption may occur if intestinal mucosal integrity is compromised.  Therapy with paromomycin should be administered cautiously in patients with inflammatory or ulcerative gastrointestinal diseases because of the potential for enhanced absorption of the drug.', '3', 'Boston Collaborative Drug Surveillance Program "Drug-induced deafness." JAMA 224 (1973):  515-6|Berk DP, Chalmers T "Deafness complicating antibiotic therapy of hepatic encephalopathy." Ann Intern Med 73 (1970):  393-6|Kunin CM "Nephrotoxicity of antibiotics." JAMA 202 (1967):  204-8|"Product Information. Humatin (paromomycin)." Parke-Davis  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15290, 26948, 'Pasireotide', 'Hepatic Insufficiency', 'The use of pasireotide causes elevations in ALT or AST.  No dose adjustment is required in patients with mild hepatic impairment, but is required for patients with moderate hepatic impairment.  The use of pasireotide should be avoided in patients with severe hepatic impairment.  Regular monitoring of liver function test is recommended and interruption of treatment should be considered if abnormal values exceeding 5 times ULN or rising values are obtained during the course of therapy.', '3', '"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15291, 26949, 'Pasireotide', 'Hepatic Insufficiency', 'The use of pasireotide causes elevations in ALT or AST.  No dose adjustment is required in patients with mild hepatic impairment, but is required for patients with moderate hepatic impairment.  The use of pasireotide should be avoided in patients with severe hepatic impairment.  Regular monitoring of liver function test is recommended and interruption of treatment should be considered if abnormal values exceeding 5 times ULN or rising values are obtained during the course of therapy.', '3', '"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15292, 26950, 'Pasireotide', 'Hepatic Insufficiency', 'The use of pasireotide causes elevations in ALT or AST.  No dose adjustment is required in patients with mild hepatic impairment, but is required for patients with moderate hepatic impairment.  The use of pasireotide should be avoided in patients with severe hepatic impairment.  Regular monitoring of liver function test is recommended and interruption of treatment should be considered if abnormal values exceeding 5 times ULN or rising values are obtained during the course of therapy.', '3', '"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15293, 26948, 'Pasireotide', 'Long QT Syndrome', 'The use of pasireotide is associated with QT prolongation.  Pasireotide should be used with caution in patients who are at significant risk of developing QT prolongation.  It is recommended to correct levels of hypokalemia and hypomagnesemia prior to starting therapy with this agent.  Assess ECG at the beginning of therapy and monitor during therapy.  Care should be taken in predisposed patients.', '2', '"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15294, 26949, 'Pasireotide', 'Long QT Syndrome', 'The use of pasireotide is associated with QT prolongation.  Pasireotide should be used with caution in patients who are at significant risk of developing QT prolongation.  It is recommended to correct levels of hypokalemia and hypomagnesemia prior to starting therapy with this agent.  Assess ECG at the beginning of therapy and monitor during therapy.  Care should be taken in predisposed patients.', '2', '"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15295, 26950, 'Pasireotide', 'Long QT Syndrome', 'The use of pasireotide is associated with QT prolongation.  Pasireotide should be used with caution in patients who are at significant risk of developing QT prolongation.  It is recommended to correct levels of hypokalemia and hypomagnesemia prior to starting therapy with this agent.  Assess ECG at the beginning of therapy and monitor during therapy.  Care should be taken in predisposed patients.', '2', '"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15296, 26948, 'Pasireotide', 'Adrenal Insufficiency', 'Treatment with somatostatin analogs may suppress the pituitary hormones other than GH/IGF-1.  It is recommended to monitor pituitary function prior to initiation of therapy and periodically during treatment, as clinically appropriate.  Patients should be monitored for and instructed on the signs and symptoms of adrenal insufficiency during therapy.  If adrenal insufficiency is suspected it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15297, 26949, 'Pasireotide', 'Adrenal Insufficiency', 'Treatment with somatostatin analogs may suppress the pituitary hormones other than GH/IGF-1.  It is recommended to monitor pituitary function prior to initiation of therapy and periodically during treatment, as clinically appropriate.  Patients should be monitored for and instructed on the signs and symptoms of adrenal insufficiency during therapy.  If adrenal insufficiency is suspected it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15298, 26950, 'Pasireotide', 'Adrenal Insufficiency', 'Treatment with somatostatin analogs may suppress the pituitary hormones other than GH/IGF-1.  It is recommended to monitor pituitary function prior to initiation of therapy and periodically during treatment, as clinically appropriate.  Patients should be monitored for and instructed on the signs and symptoms of adrenal insufficiency during therapy.  If adrenal insufficiency is suspected it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15299, 26948, 'Pasireotide', 'Bradycardia', 'Bradycardia has been reported with the use of somatostatin analogs.  It is recommended to carefully monitor patients with cardiac disorders for the development of bradycardia.  Dose adjustments of beta-blockers, calcium channel blockers, or correction of electrolyte disturbances may be necessary.  Care should be taken when initiating treatment with these agents in patients with bradycardia.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15300, 26949, 'Pasireotide', 'Bradycardia', 'Bradycardia has been reported with the use of somatostatin analogs.  It is recommended to carefully monitor patients with cardiac disorders for the development of bradycardia.  Dose adjustments of beta-blockers, calcium channel blockers, or correction of electrolyte disturbances may be necessary.  Care should be taken when initiating treatment with these agents in patients with bradycardia.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15301, 26950, 'Pasireotide', 'Bradycardia', 'Bradycardia has been reported with the use of somatostatin analogs.  It is recommended to carefully monitor patients with cardiac disorders for the development of bradycardia.  Dose adjustments of beta-blockers, calcium channel blockers, or correction of electrolyte disturbances may be necessary.  Care should be taken when initiating treatment with these agents in patients with bradycardia.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15302, 26948, 'Pasireotide', 'Cholelithiasis', 'Somatostatin analogs may reduce gallbladder motility and lead to gallstones formation.  It is recommended to assess the gallbladder prior to starting therapy and periodically thereafter.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15303, 26949, 'Pasireotide', 'Cholelithiasis', 'Somatostatin analogs may reduce gallbladder motility and lead to gallstones formation.  It is recommended to assess the gallbladder prior to starting therapy and periodically thereafter.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15304, 26950, 'Pasireotide', 'Cholelithiasis', 'Somatostatin analogs may reduce gallbladder motility and lead to gallstones formation.  It is recommended to assess the gallbladder prior to starting therapy and periodically thereafter.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15305, 26948, 'Pasireotide', 'Diabetes Mellitus', 'Elevations in blood glucose levels have been reported with the use of somatostatin analogs.  Cushing''s disease patients with poor glycemic control may be at a higher risk of developing severe hyperglycemia and associated complications, e.g., ketoacidosis.  It is recommended to assess the glycemic status of hemoglobin A1C prior to starting treatment with these agents.  Self-monitoring of blood glucose and/or FPG assessments should be done every week for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase.  If uncontrolled hyperglycemia persists, despite appropriate medical management, the dose of these agents should be reduced or discontinued.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15306, 26949, 'Pasireotide', 'Diabetes Mellitus', 'Elevations in blood glucose levels have been reported with the use of somatostatin analogs.  Cushing''s disease patients with poor glycemic control may be at a higher risk of developing severe hyperglycemia and associated complications, e.g., ketoacidosis.  It is recommended to assess the glycemic status of hemoglobin A1C prior to starting treatment with these agents.  Self-monitoring of blood glucose and/or FPG assessments should be done every week for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase.  If uncontrolled hyperglycemia persists, despite appropriate medical management, the dose of these agents should be reduced or discontinued.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15307, 26950, 'Pasireotide', 'Diabetes Mellitus', 'Elevations in blood glucose levels have been reported with the use of somatostatin analogs.  Cushing''s disease patients with poor glycemic control may be at a higher risk of developing severe hyperglycemia and associated complications, e.g., ketoacidosis.  It is recommended to assess the glycemic status of hemoglobin A1C prior to starting treatment with these agents.  Self-monitoring of blood glucose and/or FPG assessments should be done every week for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase.  If uncontrolled hyperglycemia persists, despite appropriate medical management, the dose of these agents should be reduced or discontinued.', '2', '"Product Information. Somatuline Depot (lanreotide)." Ipsen Inc  (2007):|"Product Information. Signifor (pasireotide)." Novartis Pharmaceuticals  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15308, 20291, 'Pegfilgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15309, 23444, 'Pegfilgrastim', 'Glomerulonephritis', 'Although it has been reported that renal dysfunction has no effect on the pharmacokinetics of colony stimulating factors (CSF), filgrastim and pegfilgrastim may cause glomerulonephritis.  Symptoms include swelling of the face or ankles, dark colored urine, or blood in the urine, or a decrease in urine production.  Advise patients to report signs or symptoms of glomerulonephritis immediately.  Monitoring of patients with renal dysfunction is recommended.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):|"Product Information. Granix (tbo-filgrastim)." Teva Pharmaceuticals USA  (2013):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15310, 20291, 'Pegfilgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15311, 23444, 'Pegfilgrastim', 'Leukemia, Myeloid', 'Colony stimulating factors primarily stimulates the proliferation of neutrophils but may also, theoretically, enhance tumor growth, particularly in myeloid malignancies.  Therapy with these drugs should be administered cautiously in patients with myeloid tumors.  Additionally, if used for PBPC (peripheral blood progenitor cell) collection in such patients, tumor cells may be released from the marrow and collected in the leukapheresis product.  The effect of reinfusion of tumor cells is uncertain at this time.', '3', '"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15312, 20291, 'Pegfilgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15313, 23444, 'Pegfilgrastim', 'Leukocytosis', 'Filgrastim and pegfilgrastim are growth factors for neutrophil progenitor cells.  Therefore, these should not be used in patients with leukocytosis.  If excessive white blood cell counts occur during CSF therapy, treatment should be interrupted or the dosage reduced.', '3', 'Hollingshead LM, Goa KL "Recombinant granulocyte colony-stimulating factor (rG-CSF). A review of its pharmacological properties and prospective role in neutropenic conditions." Drugs 42 (1991):  300-30|"Product Information. Neupogen (filgrastim)." Amgen  (2002):|"Product Information. Neulasta (pegfilgrastim)." Amgen  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15314, 0, 'Pegaptanib (ophthalmic)', 'Eye Infections', 'Drugs requiring intravitreal administration (including aflibercept, faricimab, pegaptanib, and ranibizumab) are contraindicated in patients with active intraocular inflammation or ocular/periocular infections; intravitreal injections have been associated with endophthalmitis.  Patients should be advised to seek immediate medical attention from an ophthalmologist if the eye becomes red, photosensitive, or painful, or if a change in vision occurs in the days following drug administration.', '3', '"Product Information. Macugen (pegaptanib ophthalmic)." OSI Pharmaceuticals Inc  (2004):|"Product Information. Lucentis (ranibizumab ophthalmic)." Genentech  (2006):|"Product Information. Eylea (aflibercept ophthalmic)." Regeneron Pharmaceuticals Inc  (2011):|"Product Information. Vabysmo (faricimab ophthalmic)." Genentech  (2022):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15315, 0, 'Pegaspargase', 'Hemorrhagic Disorders', 'The use of pegaspargase is contraindicated in patients who developed significant bleeding with previous L-asparaginase therapy.  Pegaspargase interferes with coagulation factors, and both thrombosis and hemorrhage have been observed.  Therapy with pegaspargase should be administered with extreme caution to patients with or predisposed to coagulopathies.  Patients should be instructed to immediately report any signs or symptoms of thrombosis or bleeding.  Close clinical monitoring of hematopoetic function and coagulation profiles is recommended.', '3', '"Product Information. Oncaspar (pegaspargase)." Rhone Poulenc Rorer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15316, 0, 'Pegaspargase', 'Pancreatitis', 'The use of pegaspargase is contraindicated in patients with or a history of pancreatitis.  Pegaspargase can cause decreased insulin synthesis or inflammation and/or necrosis of cells of the pancreas.  Fulminant and fatal pancreatitis has occurred.  Clinical monitoring of pancreatic function, including serum amylase levels, is recommended.', '3', '"Product Information. Oncaspar (pegaspargase)." Rhone Poulenc Rorer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15317, 0, 'Pegaspargase', 'Liver Diseases', 'Reversible liver abnormalities such as elevated liver transaminase and bilirubin levels and decreased albumin synthesis have been reported during pegaspargase therapy.  Fatty changes and liver failure have occurred.  Patients should be instructed to immediately report any sign or symptoms of hepatic dysfunction such as jaundice, dark urine, right upper quadrant pain, or anorexia.  Therapy with pegaspargase should be administered cautiously to patients with or predisposed to compromised hepatic function.  Clinical monitoring of hepatic function is recommended.', '2', '"Product Information. Oncaspar (pegaspargase)." Rhone Poulenc Rorer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15318, 0, 'Pegaspargase', 'Hyperglycemia', 'Hyperglycemia requiring insulin therapy has been reported during pegaspargase therapy.  Therapy with pegaspargase should be administered cautiously to patients with diabetes mellitus.', '2', '"Product Information. Oncaspar (pegaspargase)." Rhone Poulenc Rorer  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15319, 0, 'Patiromer', 'Gastrointestinal Diseases', 'The use of patiromer should be avoided in patients with severe constipation, bowel obstruction or impaction, including abnormal post-operative bowel motility disorders, as this agent may be ineffective and may worsen gastrointestinal conditions.  Therapy with patiromer should be administered cautiously in patients with a history of bowel obstruction or major gastrointestinal surgery, severe gastrointestinal disorders, or swallowing disorders.', '3', '"Product Information. Veltassa (patiromer)." Relypsa, Inc.  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15320, 0, 'Patiromer', 'Hypomagnesemia 1, Intestinal', 'Patiromer binds to magnesium in the colon, which can lead to hypomagnesemia.  It is recommended to monitor serum magnesium concentrations during therapy.  Therapy with patiromer should be administered cautiously in patients with or predisposed to magnesium deficiency.  Consider magnesium supplementation in patients who develop low serum magnesium levels.', '2', '"Product Information. Veltassa (patiromer)." Relypsa, Inc.  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15321, 0, 'Pegvisomant', 'Diabetes Mellitus', 'Pegvisomant is an analog of human growth hormone (GH) that selectively binds to growth hormone (GH) receptors on cell surfaces, where it blocks the binding of endogenous GH, and thus interferes with GH signal transduction.  The use of growth hormones opposes the effects of insulin on carbohydrate metabolism by decreasing insulin sensitivity; therefore, glucose intolerance may improve in some patients treated with pegvisomant.  Diabetic patients should be monitored closely, and the doses of anti-diabetic drugs may be reduced as necessary to avoid hypoglycemia.  Blood glucose levels should be evaluated as appropriate.', '2', '"Product Information. Somavert (pegvisomant)." Pharmacia and Upjohn  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15322, 0, 'Pegvisomant', 'Liver Diseases', 'Asymptomatic, transient elevations in transaminases up to 15 times ULN have been observed in patients treated with pegvisomant.  Baseline serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), serum total bilirubin (TBIL), and alkaline phosphatase (ALP) levels should be obtained prior to initiating therapy with pegvisomant.  Care should be exercised when using this agent in patients with liver dysfunction and its use should be used in accordance with the information presented in the manufacturer prescribing information with respect to liver test abnormalities.', '2', '"Product Information. Somavert (pegvisomant)." Pharmacia and Upjohn  (2003):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15323, 0, 'Pegademase', 'Blood Platelet Disorders', 'Pegademase bovine should be used with caution in patients with thrombocytopenia.  This agent should not be used in patients with severe thrombocytopenia.  Pegademase is administered by IM injection and the risk of bleeding is increased in the presence of severe thrombocytopenia.  Therapy with pegademase bovine should be administered cautiously in patients with coagulation or platelet function disorders.', '3', '"Product Information. Adagen (pegademase bovine)." Enzon Inc  (2001):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15324, 0, 'Acetaminophen', 'Alcoholism', 'Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP).  Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen.  Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day.  In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications.  Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.  They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.', '3', 'Kaysen GA, Pond SM, Roper MH, Menke DJ, Marrama MA "Combined hepatic and renal injury in alcoholics during therapeutic use of acetaminophen." Arch Intern Med 145 (1985):  2019-23|O''Dell JR, Zetterman RK, Burnett DA "Centrilobular hepatic fibrosis following acetaminophen-induced hepatic necrosis in an alcoholic." JAMA 255 (1986):  2636-7|Seeff LB, Cuccherini BA, Zimmerman HJ, Adler E, Benjamin SB "Acetaminophen hepatotoxicity in alcoholics." Ann Intern Med 104 (1986):  399-404|McClain CJ, Kromhout JP, Peterson FJ, Holtzman JL "Potentiation of acetaminophen hepatotoxicity by alcohol." JAMA 244 (1980):  251-3|Kartsonis A, Reddy KR, Schiff ER "Alcohol, acetaminophen, and hepatic necrosis." Ann Intern Med 105 (1986):  138-9|Prescott LF, Critchley JA "Drug interactions affecting analgesic toxicity." Am J Med 75 (1983):  113-6|"Product Information. Tylenol (acetaminophen)." McNeil Pharmaceutical  (2002):|Whitcomb DC, Block GD "Association of acetaminopphen hepatotoxicity with fasting and ethanol use." JAMA 272 (1994):  1845-50|Bonkovsky HL "Acetaminophen hepatotoxicity, fasting, and ethanol." JAMA 274 (1995):  301|Nelson EB, Temple AR "Acetaminophen hepatotoxicity, fasting, and ethanol." JAMA 274 (1995):  301|Zimmerman HJ, Maddrey WC "Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure." Hepatology 22 (1995):  767-73', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15325, 0, 'Acetaminophen', 'Liver Diseases', 'Acetaminophen is primarily metabolized in the liver to inactive forms.  However, small quantities are converted by minor pathways to metabolites that can cause hepatotoxicity or methemoglobinemia.  Patients with hepatic impairment may be at increased risk of toxicity due to increased minor metabolic pathway activity.  Likewise, chronic or overuse of acetaminophen can saturate the primary hepatic enzymes and lead to increased metabolism by minor pathways.  Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen.  Therapy with acetaminophen should be administered cautiously in patients with hepatic insufficiency.  Clinical monitoring of hepatic function is recommended.  Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications.  Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.', '3', 'Gillette JR "An integrated approach to the study of chemically reactive metabolites of acetaminophen." Arch Intern Med 141 (1981):  375-9|Arnman R, Olsson R "Elimination of paracetamol in chronic liver disease." Acta Hepatogastroenterol (Stuttg) 25 (1978):  283-6|Clements JA, Critchley JA, Prescott LF "The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man." Br J Clin Pharmacol 18 (1984):  481-5|Forrest JA, Adriaenssens P, Finlayson ND, Prescott LF "Paracetamol metabolism in chronic liver disease." Eur J Clin Pharmacol 15 (1979):  427-31|Venkataramanan R, Kalp K, Rabinovitch M, et al. "Conjugative drug metabolism in liver transplant patients." Transplant Proc 21 (1989):  2455|"Product Information. Tylenol (acetaminophen)." McNeil Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15326, 0, 'Acetaminophen', 'Phenylketonurias', 'Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet).  Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion.  Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine.  The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).', '2', '"Product Information. Tylenol (acetaminophen)." McNeil Pharmaceutical  (2002):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15327, 14520, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15328, 14521, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15329, 14522, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15330, 14655, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15331, 14656, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15332, 14657, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15333, 18005, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15334, 18518, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15335, 18523, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15336, 18524, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15337, 18525, 'Avanafil', 'Cardiovascular Diseases', 'The use of phosphodiesterase-5 (PDE5) inhibitors is not recommended in patients with preexisting cardiovascular disease for whom sexual activity is inadvisable due to the potential cardiac risk.  Physicians should also consider the vasodilatory effect of these drugs and whether they may adversely affect patients with underlying cardio- and/or cerebrovascular conditions, in particular those who have suffered a myocardial infarction, stroke, or life-threatening arrhythmia within the last 6 months; those with resting hypotension (BP < 90/50) or hypertension (BP > 170/110); and those with unstable angina associated with cardiac failure or coronary artery disease.  There are no controlled clinical data on the safety or efficacy in such patients.  Other adverse cardiovascular effects reported include angina pectoris, myocardial infarction, AV block, ventricular arrhythmia, tachycardia, palpitation, hypotension, postural hypotension, syncope, cerebral thrombosis, cerebrovascular hemorrhage, transient ischemic attack, cardiac arrest, heart failure, and hypertension.  Many of these events occurred in patients with cardiovascular risk factors and during or shortly after sexual activity.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Feenstra J, vanDriePierik RJHM, Lacle CF, Stricker BHC "Acute myocardial infarction associated with sildenafil." Lancet 352 (1998):  957-8|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zusman RM "Cardiovascular data on sildenafil citrate - Introduction." Am J Cardiol 83 (1999):  c1-2|Conti CR, Pepine CJ, Sweeney M "Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease." Am J Cardiol 83 (1999):  c29-34|Zusman RM, Morales A, Glasser DB, Osterloh IH "Overall cardiovascular profile of sildenafil citrate." Am J Cardiol 83 (1999):  c35-44|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Kloner RA, Zusman RM "Cardiovascular effects of sildenafil citrate and recommendations for its use." Am J Cardiol 84 (1999):  n11-7|Awan GM, Calderon E, Dawood G, Alpert MA "Acute, symptomatic atrial fibrillation after sildenafil citrate therapy in a patient with hypertrophic obstructive cardiomyopathy." Am J Med Sci 320 (2000):  69-71|Kloner RA "Cardiovascular risk and sildenafil." Am J Cardiol 86 (2000):  f57-61|Moreira SG, Brannigan RE, Spitz A, Orejuela FJ, Lipshultz LI, Kim ED "Side-effect profile of sildenafil citrate (Viagra) in clinical practice." Urology 56 (2000):  474-6|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|Malozowski S, Sahlroot JT "Hemodynamic effects of sildenafil." N Engl J Med 343 (2000):  967-8|Dunn N "Cardiovascular events in users of sildenafil - Paper does not provide any reassurance." Br Med J 323 (2001):  50-1|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|Curran M, Keating G "Tadalafil." Drugs 63 (2003):  2203-12; discussion 2213-4|Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15338, 14520, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15339, 14521, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15340, 14522, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15341, 14655, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15342, 14656, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15343, 14657, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15344, 18005, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15345, 18518, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15346, 18523, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15347, 18524, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15348, 18525, 'Avanafil', 'Kidney Diseases', 'The plasma clearance of phosphodiesterase-5 (PDE5) inhibitors may be decreased in patients with severe renal impairment, resulting in drug accumulation.  Therapy with these agents should be avoided in patients with severe renal disease or on renal dialysis.  Dose adjustments might be needed based on individual renal assessment and tolerability if used in these patients.', '3', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15349, 14520, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15350, 14521, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15351, 14522, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15352, 14655, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15353, 14656, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15354, 14657, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15355, 18005, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15356, 18518, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15357, 18523, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15358, 18524, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15359, 18525, 'Avanafil', 'Priapism', 'Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours) have been reported during treatment with phosphodiesterase-5 (PDE 5) inhibitors.  Priapism may result in penile tissue damage and permanent loss of potency if not treated promptly.  These agents should be used cautiously in patients with conditions that may predispose them to priapism such as sickle cell anemia, multiple myeloma, or leukemia, and those with anatomical deformation of the penis (such as angulation, cavernosal fibrosis, or Peyronie''s disease).  If an erection persists longer than 4 hours, the patient should seek immediate medical assistance.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Kassim AA, Fabry ME, Nagel RL "Acute priapism associated with the use of sildenafil in a patient with sickle cell trait." Blood 95 (2000):  1878-9|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15360, 14520, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15361, 14521, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15362, 14522, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15363, 14655, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15364, 14656, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15365, 14657, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15366, 18005, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15367, 18518, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15368, 18523, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15369, 18524, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15370, 18525, 'Avanafil', 'Alcoholism', 'Alcohol consumption may intensify the pressure-lowering effects of mild vasodilators, such as phosphodiesterase 5 (PDE5) inhibitors.  Therefore, patients that consume alcohol should be warned to limit alcohol intake while receiving these agents.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15371, 14520, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15372, 14521, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15373, 14522, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15374, 14655, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15375, 14656, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15376, 14657, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15377, 18005, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15378, 18518, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15379, 18523, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15380, 18524, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15381, 18525, 'Avanafil', 'Hearing Loss', 'Use of phosphodiesterase-5 (PDE5) inhibitors has been associated with sudden decrease or loss of hearing, which may be accompanied by tinnitus or dizziness.  Patients with hearing problems should stop taking these agents and seek prompt medical care.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15382, 14520, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15383, 14521, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15384, 14522, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15385, 14655, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15386, 14656, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15387, 14657, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15388, 18005, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15389, 18518, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15390, 18523, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15391, 18524, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15392, 18525, 'Avanafil', 'Liver Diseases', 'Phosphodiesterase 5 (PDE-5) inhibitors are cleared predominantly by hepatic metabolism.  The pharmacokinetic disposition of these agents has not been assessed in patients with severe hepatic impairment.  No dosage modification is recommended for patients with mild to moderate hepatic impairment, however, therapy with these agents should not be administered to patients with severe hepatic impairment.  In patients with mild hepatic impairment a lower dose of these agents should be used as initial therapy.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15393, 14520, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15394, 14521, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15395, 14522, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15396, 14655, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15397, 14656, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15398, 14657, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15399, 18005, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15400, 18518, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15401, 18523, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15402, 18524, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15403, 18525, 'Avanafil', 'Retinitis Pigmentosa', 'Phosphodiesterase-5 (PDE5) inhibitors have been associated with transient impairment of color discrimination (blue/green) and blue- or color-tinged vision.  These agents also inhibit phosphodiesterase-6 (PDE6), to a much lesser extent, which is involved in phototransduction in the retina.  There are no controlled clinical data on the safety in patients with retinitis pigmentosa, a minority of whom may have genetic disorders of retinal phosphodiesterases.  Therapy with these agents should be avoided in such patients.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA "Oral sildenafil in the treatment of erectile dysfunction." N Engl J Med 338 (1998):  1397-404|Goldenberg MM "Safety and efficacy of sildenafil citrate in the treatment of male erectile dysfunction." Clin Ther 20 (1998):  1033-48|Zrenner E "No cause for alarm over retinal side-effects of sildenafil." Lancet 353 (1999):  340-1|Vobig MA, Klotz T, Staak M, BartzSchmidt KU, Engelmann U, Walter P "Retinal side-effects of sildenafil." Lancet 353 (1999):  375|Marmor MF "Sildenafil (Viagra) and ophthalmology." Arch Ophthalmol 117 (1999):  518-9|Montorsi F, McDermott TED, Morgan R, Olsson A, Schultz A, Kirkeby HJ, Osterloh IH "Efficacy and safety of fixed-dose oral sildenafil in the treatment of erectile dysfunction of various etiologies." Urology 53 (1999):  1011-8|Vobig MA "Retinal side-effects of sildenafil." Lancet 353 (1999):  1442|McMahon CG, Smali R, Johnson H "Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction." J Urol 164 (2000):  1192-6|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15404, 14520, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15405, 14521, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15406, 14522, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15407, 14655, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15408, 14656, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15409, 14657, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15410, 18005, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15411, 18518, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15412, 18523, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15413, 18524, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15414, 18525, 'Avanafil', 'Epilepsy', 'The use of phosphodiesterase 5 (PDE-5) inhibitors has been associated with seizures.  Therapy with these agents should be administered cautiously in patients with preexisting seizure disorders.', '2', '"Product Information. Viagra (sildenafil)." Pfizer U.S. Pharmaceuticals  (2001):|"Product Information. Levitra (vardenafil)." Bayer  (2003):|"Product Information. Cialis (tadalafil)." Lilly, Eli and Company  (2003):|"Product Information. Revatio (sildenafil)." Pfizer U.S. Pharmaceuticals Group  (2005):|"Product Information. Adcirca (tadalafil)." United Therapeutics Corporation  (2009):|"Product Information. Stendra (avanafil)." Vivus Inc  (2012):|"Product Information. Staxyn (vardenafil)." Merck & Co., Inc  (2014):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15415, 4034, 'Peginterferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15416, 18116, 'Peginterferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15417, 18117, 'Peginterferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15418, 20910, 'Peginterferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15419, 20911, 'Peginterferon alfa-2b', 'Kidney Diseases', 'Proteinuria (rare), not associated with a decrease in serum protein, is the most common renal toxicity observed with interferon- alfa therapy.  Increased BUN and serum creatinine levels, hematuria, acute renal failure and nephrotic syndrome have also been reported.  Therapy with interferon alfa should be administered cautiously to patients with severe renal dysfunction.  Renal function should be evaluated in all patients before initiation of interferon- alfa therapy.  In addition, patients with any degree of renal impairment should be carefully monitored for laboratory abnormalities and decreased creatinine clearance.  A reduced dose of medication is recommended in patients with low CrCl (less than 50 mL/min - 30 mL/min).', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15420, 4034, 'Peginterferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15421, 18116, 'Peginterferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15422, 18117, 'Peginterferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15423, 20910, 'Peginterferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15424, 20911, 'Peginterferon alfa-2b', 'Autoimmune Diseases', 'Antiviral interferons may exacerbate autoimmune disorders such as myositis, thyroiditis, systemic lupus erythematosus, rheumatoid arthritis, psoriasis, or autoimmune hepatitis.  Therapy should be avoided or administered with extreme caution in patients with autoimmune disorders.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15425, 4034, 'Peginterferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15426, 18116, 'Peginterferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15427, 18117, 'Peginterferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15428, 20910, 'Peginterferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15429, 20911, 'Peginterferon alfa-2b', 'Heart Diseases', 'Hypertension, arrhythmias, angina, myocardial infarction, cardiomyopathy, and congestive heart failure have been reported during interferon therapy.  Therapy with interferons should be administered with caution in patients with compromised cardiac function.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15430, 4034, 'Peginterferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15431, 18116, 'Peginterferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15432, 18117, 'Peginterferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15433, 20910, 'Peginterferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15434, 20911, 'Peginterferon alfa-2b', 'Central Nervous System Diseases', 'Reversible CNS effects such as seizures, mental status changes, manic behavior or psychotic reactions, gait disturbances, and dizziness have occurred in patients receiving interferons.  Therapy with interferons should be administered cautiously in patients with or predisposed to seizures, psychiatric disorders, or conditions affecting posture or gait.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15435, 4034, 'Peginterferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15436, 18116, 'Peginterferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15437, 18117, 'Peginterferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15438, 20910, 'Peginterferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15439, 20911, 'Peginterferon alfa-2b', 'Depressive Disorder', 'Interferons (alfa or beta) can induce depression and suicidal behavior.  Suicidal attempts and suicides have been reported.  Therapy with interferons (alfa or beta) should be administered cautiously to patients with or predisposed to mental depression.  Clinical monitoring of psychological status is recommended.', '3', '"Product Information. Betaseron (interferon beta-1b)." Berlex Laboratories  (2002):|"Product Information. Avonex (interferon beta-1a)." Biogen  (2001):|"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15440, 4034, 'Peginterferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15441, 18116, 'Peginterferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15442, 18117, 'Peginterferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15443, 20910, 'Peginterferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15444, 20911, 'Peginterferon alfa-2b', 'Hypothyroidism', 'Thyroid abnormalities, hypothyroidism or hyperthyroidism, have been reported in patients administered interferons.  Therapy with interferons should be administered cautiously to patients with thyroid dysfunction.  If thyroid control cannot be maintained within normal limits with medication, interferon-alfa should be discontinued.  Clinical monitoring of thyroid function is recommended.', '3', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15445, 4034, 'Peginterferon alfa-2b', 'Hepatitis, Autoimmune', 'The use of peginterferons alfa are contraindicated in patients with autoimmune hepatitis.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15446, 18116, 'Peginterferon alfa-2b', 'Hepatitis, Autoimmune', 'The use of peginterferons alfa are contraindicated in patients with autoimmune hepatitis.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15447, 18117, 'Peginterferon alfa-2b', 'Hepatitis, Autoimmune', 'The use of peginterferons alfa are contraindicated in patients with autoimmune hepatitis.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15448, 20910, 'Peginterferon alfa-2b', 'Hepatitis, Autoimmune', 'The use of peginterferons alfa are contraindicated in patients with autoimmune hepatitis.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15449, 20911, 'Peginterferon alfa-2b', 'Hepatitis, Autoimmune', 'The use of peginterferons alfa are contraindicated in patients with autoimmune hepatitis.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15450, 4034, 'Peginterferon alfa-2b', 'Liver Failure', 'The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15451, 18116, 'Peginterferon alfa-2b', 'Liver Failure', 'The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15452, 18117, 'Peginterferon alfa-2b', 'Liver Failure', 'The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15453, 20910, 'Peginterferon alfa-2b', 'Liver Failure', 'The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15454, 20911, 'Peginterferon alfa-2b', 'Liver Failure', 'The use of peginterferons alfa are contraindicated in patients with hepatic decompensation (Child-Pugh score greater than 6, class B or C) in cirrhotic patients before treatment, and in patients with hepatic decompensation (Child-Pugh score greater or equal to 6) that have chronic hepatitis C coinfected with HIV.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15455, 4034, 'Peginterferon alfa-2b', 'Hemoglobinopathies', 'The use of peginterferon alfa-2b is contraindicated in patients with hemoglobinopathies such as, thalassemia major, and sickle-cell anemia.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15456, 18116, 'Peginterferon alfa-2b', 'Hemoglobinopathies', 'The use of peginterferon alfa-2b is contraindicated in patients with hemoglobinopathies such as, thalassemia major, and sickle-cell anemia.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15457, 18117, 'Peginterferon alfa-2b', 'Hemoglobinopathies', 'The use of peginterferon alfa-2b is contraindicated in patients with hemoglobinopathies such as, thalassemia major, and sickle-cell anemia.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15458, 20910, 'Peginterferon alfa-2b', 'Hemoglobinopathies', 'The use of peginterferon alfa-2b is contraindicated in patients with hemoglobinopathies such as, thalassemia major, and sickle-cell anemia.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15459, 20911, 'Peginterferon alfa-2b', 'Hemoglobinopathies', 'The use of peginterferon alfa-2b is contraindicated in patients with hemoglobinopathies such as, thalassemia major, and sickle-cell anemia.', '3', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15460, 4034, 'Peginterferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15461, 18116, 'Peginterferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15462, 18117, 'Peginterferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15463, 20910, 'Peginterferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15464, 20911, 'Peginterferon alfa-2b', 'Colitis', 'Fatal and nonfatal ulcerative or hemorrhagic/ischemic colitis have been observed within 12 weeks of the start of alpha interferon treatment.  Abdominal pain, bloody diarrhea, and fever are the typical manifestations.  Treatment should be discontinued immediately in patients who develop these signs and symptoms.  The colitis usually resolves within 1 to 3 weeks of discontinuation of alpha interferons.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15465, 4034, 'Peginterferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15466, 18116, 'Peginterferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15467, 18117, 'Peginterferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15468, 20910, 'Peginterferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15469, 20911, 'Peginterferon alfa-2b', 'Diabetes Mellitus', 'Flu-like symptoms frequently associated with interferon-alfa therapy can precipitate ketoacidosis in diabetic patients.  Therapy with interferon alfa should be administered cautiously in patients with diabetes mellitus.  Clinical monitoring of blood glucose concentrations and anti-diabetic therapy is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15470, 4034, 'Peginterferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15471, 18116, 'Peginterferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15472, 18117, 'Peginterferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15473, 20910, 'Peginterferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15474, 20911, 'Peginterferon alfa-2b', 'Bone Marrow Failure Disorders', 'Interferons (alfa and gamma) induce a dose-dependent, generally mild, myelosuppression.  Leukopenia is the primary manifestation.  Thrombocytopenia and anemia occur less frequently.  Therapy with interferons (alfa and gamma) should be administered cautiously to patients with bone marrow suppression.  Clinical monitoring of hematopoietic function is recommended.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):|"Product Information. BESREMi (ropeginterferon alfa-2b)." PharmaEssentia USA Corp  (2021):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15475, 4034, 'Peginterferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15476, 18116, 'Peginterferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15477, 18117, 'Peginterferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15478, 20910, 'Peginterferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15479, 20911, 'Peginterferon alfa-2b', 'Peripheral Nervous System Diseases', 'Paresthesia and numbness have been reported during interferon therapy.  Therapy with interferons should be administered cautiously in patients with or predisposed to peripheral neuropathy.', '2', '"Product Information. Intron A (interferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Infergen (interferon alfacon-1)." Amgen  (2001):|"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15480, 4034, 'Peginterferon alfa-2b', 'Endocrine System Diseases', 'Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus.  Treatment should be administered with caution on patients with these conditions.  Treatment should not be initiated if the condition cannot be effectively treated by medication.  Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15481, 18116, 'Peginterferon alfa-2b', 'Endocrine System Diseases', 'Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus.  Treatment should be administered with caution on patients with these conditions.  Treatment should not be initiated if the condition cannot be effectively treated by medication.  Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15482, 18117, 'Peginterferon alfa-2b', 'Endocrine System Diseases', 'Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus.  Treatment should be administered with caution on patients with these conditions.  Treatment should not be initiated if the condition cannot be effectively treated by medication.  Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15483, 20910, 'Peginterferon alfa-2b', 'Endocrine System Diseases', 'Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus.  Treatment should be administered with caution on patients with these conditions.  Treatment should not be initiated if the condition cannot be effectively treated by medication.  Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15484, 20911, 'Peginterferon alfa-2b', 'Endocrine System Diseases', 'Peginterferons alfa can cause or aggravate hypothyroidism, hyperthyroidism, hyperglycemia, hypoglycemia and diabetes mellitus.  Treatment should be administered with caution on patients with these conditions.  Treatment should not be initiated if the condition cannot be effectively treated by medication.  Therapy should be discontinued if any of these conditions develops during treatment and it cannot be controlled with medication.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15485, 4034, 'Peginterferon alfa-2b', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15486, 18116, 'Peginterferon alfa-2b', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15487, 18117, 'Peginterferon alfa-2b', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15488, 20910, 'Peginterferon alfa-2b', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15489, 20911, 'Peginterferon alfa-2b', 'Eye Diseases', 'Decrease or loss of vision, retinopathy including macular edema, retinal artery or vein thrombosis, retinal hemorrhages and cotton wool spots, optic neuritis, papilledema, and serious retinal detachment can be induced or aggravated by alpha interferons.  All patients should receive an eye examination at baseline and caution should be exercised in patients with preexisting ophthalmologic disorders.  Patients should have periodic ophthalmologic exams during treatment.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15490, 4034, 'Peginterferon alfa-2b', 'Pancreatitis', 'Fatal and nonfatal pancreatitis has been observed in patients treated with alpha interferon.  Therapy should be suspended in patients with signs and symptoms suggestive of pancreatitis and discontinued in patients diagnosed with pancreatitis.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15491, 18116, 'Peginterferon alfa-2b', 'Pancreatitis', 'Fatal and nonfatal pancreatitis has been observed in patients treated with alpha interferon.  Therapy should be suspended in patients with signs and symptoms suggestive of pancreatitis and discontinued in patients diagnosed with pancreatitis.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15492, 18117, 'Peginterferon alfa-2b', 'Pancreatitis', 'Fatal and nonfatal pancreatitis has been observed in patients treated with alpha interferon.  Therapy should be suspended in patients with signs and symptoms suggestive of pancreatitis and discontinued in patients diagnosed with pancreatitis.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15493, 20910, 'Peginterferon alfa-2b', 'Pancreatitis', 'Fatal and nonfatal pancreatitis has been observed in patients treated with alpha interferon.  Therapy should be suspended in patients with signs and symptoms suggestive of pancreatitis and discontinued in patients diagnosed with pancreatitis.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15494, 20911, 'Peginterferon alfa-2b', 'Pancreatitis', 'Fatal and nonfatal pancreatitis has been observed in patients treated with alpha interferon.  Therapy should be suspended in patients with signs and symptoms suggestive of pancreatitis and discontinued in patients diagnosed with pancreatitis.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15495, 4034, 'Peginterferon alfa-2b', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15496, 18116, 'Peginterferon alfa-2b', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15497, 18117, 'Peginterferon alfa-2b', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15498, 20910, 'Peginterferon alfa-2b', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15499, 20911, 'Peginterferon alfa-2b', 'Respiration Disorders', 'Dyspnea, pulmonary infiltrates, pneumonia, bronchiolitis, pulmonary hypertension, and other pulmonary disorders resulting in respiratory failure and/or death may be induced or aggravated by alpha interferon therapy.  Caution should be used when used in patients with preexisting pulmonary disorders.', '2', '"Product Information. PEG-Intron (peginterferon alfa-2b)." Schering Corporation  (2001):|"Product Information. Pegasys (peginterferon alfa-2a)." Roche Laboratories  (2002):|"Product Information. Sylatron (peginterferon alfa-2b)." Schering-Plough Corporation  (2015):', 'DDInter', 0);
INSERT OR IGNORE INTO disease_interactions (id, med_id, trade_name, disease_name, interaction_text, severity, reference_text, source, created_at) VALUES (15500, 21406, 'Pembrolizumab', 'Infections', 'Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression.  The use of these drugs may be contraindicated in patients with known infectious diseases.  All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy.  Close clinical monitoring of hematopoietic function is recommended.', '3', 'Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992):  314-5|"Product Information. Methotrexate (methotrexate)." Lederle Laboratories  (2002):|"Product Information. Platinol (cisplatin)." Bristol-Myers Squibb  (2001):|"Product Information. Vepesid (etoposide)." Bristol-Myers Squibb  (2001):|"Product Information. Novantrone (mitoxantrone)." Immunex Corporation  (2001):|"Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb  (2001):|"Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb  (2001):|"Product Information. Thiotepa (thiotepa)." Hikma USA (formerly West-Ward Pharmaceutical Corporation)  (2001):|Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994):  407-8|Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990):  833-4|Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992):  1396-7|Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991):  671|"Product Information. Fludara (fludarabine)." Berlex Laboratories  (2001):|"Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Matulane (procarbazine)." Roche Laboratories  (2001):|"Product Information. DTIC-Dome (dacarbazine)." Bayer  (2001):|"Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn  (2001):|"Product Information. Leustatin (cladribine)." Ortho Biotech Inc  (2001):|"Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company  (2001):|"Product Information. Hycamtin (topotecan)." SmithKline Beecham  (2001):|"Product Information. Taxotere (docetaxel)." Rhone Poulenc Rorer  (2001):|"Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb  (2001):|"Product Information. Nipent (pentostatin)." Hospira Inc  (2001):|"Product Information. Tabloid (thioguanine)." Prasco Laboratories  (2001):|"Product Information. Xeloda (capecitabine)." Roche Laboratories  (2001):|"Product Information. Alkeran (melphalan)." Glaxo Wellcome  (2022):|"Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome  (2001):|"Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.|"Product Information. Doxil (doxorubicin liposomal)." Sequus Pharmaceuticals Inc  (2001):|"Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn  (2001):|"Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation  (2001):|"Product Information. Jevtana (cabazitaxel)." sanofi-aventis  (2010):|"Product Information. Halaven (eribulin)." Eisai Inc  (2010):|"Product Information. Keytruda (pembrolizumab)." Merck & Co., Inc  (2014):|"Product Information. Blincyto (blinatumomab)." Amgen USA  (2014):|"Product Information. Opdivo (nivolumab)." Bristol-Myers Squibb  (2014):|"Product Information. Unituxin (dinutuximab)." United Therapeutics Corporation  (2015):|"Product Information. Empliciti (elotuzumab)." Bristol-Myers Squibb  (2015):|"Product Information. Pepaxto (melphalan flufenamide)." Oncopeptides Inc.  (2021):', 'DDInter', 0);
